Ivermectin is a Nobel Prize-winning wonder drug – but not for COVID-19

Ivermectin has been a lifesaving drug for people with parasitic infections like river blindness and strongyloidiasis. But taking it for COVID-19 may result in the opposite effect.

Jeffrey R. Aeschlimann, Associate Professor of Pharmacy, University of Connecticut • conversation
Oct. 14, 2021 ~10 min

Anxious about going out into the world? You're not alone, but there's help

As more people become vaccinated, many of them are eager to resume their social lives. And yet, many are fearful, and some may not want to return to life as they previously experienced it.

Claudia Finkelstein, Associate Professor of Medicine, Michigan State University • conversation
April 8, 2021 ~9 min


Sketchy darknet websites are taking advantage of the COVID-19 pandemic – buyer beware

The global pandemic has fueled illicit online sales of COVID-19 commodities, some of which are dangerous or illegal. Researchers are assessing the size and reach of this underground market.

David Maimon, Associate Professor of Criminal Justice and Criminology, Georgia State University • conversation
Aug. 19, 2020 ~7 min

Why hydroxychloroquine and chloroquine don't block coronavirus infection of human lung cells

A new study not only shows that the malarial drug chloroquine doesn't block SARS-CoV-2 from infecting lung cells, but also explains why.

Katherine Seley-Radtke, Professor of Chemistry and Biochemistry and President-Elect of the International Society for Antiviral Research, University of Maryland, Baltimore County • conversation
July 23, 2020 ~5 min

Why hydroxychloroquine and chloroquine don't block SARS-CoV-2 infection of human lung cells

A new study not only shows that the malarial drug chloroquine doesn't block SARS-CoV-2 from infecting lung cells, but also explains why.

Katherine Seley-Radtke, Professor of Chemistry and Biochemistry and President-Elect of the International Society for Antiviral Research, University of Maryland, Baltimore County • conversation
July 23, 2020 ~5 min

When Trump pushed hydroxychloroquine to treat COVID-19, hundreds of thousands of prescriptions followed despite little evidence that it worked

When news reports tout a drug, people get interested, even if the benefits are unproven. Patient hopes, requests and demands can easily turn into real prescriptions in their doctor's office.

Richard L. Kravitz, Professor of Health Policy and Internal Medicine, University of California, Davis • conversation
July 9, 2020 ~10 min

Retractions and controversies over coronavirus research show that the process of science is working as it should

Severe scrutiny of two major papers, including one about the effectiveness of hydroxychloroquine, is part of science's normal process of self-correction.

Mark R. O'Brian, Professor and Chair of Biochemistry, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, The State University of New York • conversation
July 6, 2020 ~9 min

Which drugs and therapies are proven to work, and which ones don't, for COVID-19?

During the last six months, news reports have mentioned dozens of drugs that may be effective against the new coronavirus. Here we lay out the evidence and reveal which ones are proven to work. Or not.

William Petri, Professor of Medicine, University of Virginia • conversation
July 1, 2020 ~7 min


Could pressure for COVID-19 drugs lead the FDA to lower its standards?

The FDA has sped up its approval process for coronavirus treatments, creating a new division to expedite the regulatory process. But is safety being sidelined for speed?

Leigh Turner, Associate Professor, University of Minnesota Center for Bioethics, School of Public Health, & College of Pharmacy, University of Minnesota • conversation
June 10, 2020 ~10 min

Hydroxychloroquine for COVID-19: A new review of several studies shows flaws in research and no benefit

Our expert assessed all the controlled studies so far on hydroxychloroquine. His findings may surprise you.

C. Michael White, Professor and Head of the Department of Pharmacy Practice, University of Connecticut • conversation
May 28, 2020 ~7 min

/

2